NSE: AMRUTANJAN · BSE: 590006 · ISIN INE098F01031
Amrutanjan Health Care Limited stock analysis
Amrutanjan Health Care Limited ranks #1476 in the TickerSutra evidence-ranked universe with a score of 53/100 and 95% data confidence. The latest captured fundamentals show ROCE of 24.8%, quarterly sales growth of 9.5% and quarterly profit growth of -29.8%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 24.8%
- Low debt/equity of 0.01×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- CFO/EBITDA is below 0.6×
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹406cr | ₹80cr | ₹67cr | 20.0% |
| 2023 | ₹380cr | ₹45cr | ₹40cr | 12.0% |
| 2024 | ₹421cr | ₹52cr | ₹45cr | 12.0% |
| 2025 | ₹452cr | ₹58cr | ₹51cr | 13.0% |
| 2026 | ₹503cr | ₹76cr | ₹58cr | 15.0% |
| TTM | ₹511cr | ₹73cr | ₹54cr | 14.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Amrutanjan Health Care Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineAmrutanjan Health Care Ltd-$ - 590006 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 23 Sept 2026Proceedings of 89th Annual General Meeting
RoutineShareholders meetingNSE · 23 Sept 2026Amrutanjan Health Care Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 23, 2026
MANAGEMENT COMMENTARY
Signals from filed documents
Africa continued to be the largest contributor to export revenue, accounting for 81% of total exports in FY26. While the contribution from the Middle East and Southeast Asia moderated during the year, revenues from other international markets doubled compared with the previous year, indicating encouraging progress in geographical diversification. From a category perspective, the Head segment regained momentum during
Continued investments in these channels will focus on expanding consumer reach, enhancing accessibility and convenience, and creating sustainable growth opportunities for the Company. Exports: Expanding Global Presence and Strengthening Export Growth AHCL’s Export business delivered its strongest performance in the last 13 years, recording revenue of I 11.15 crore in FY26, representing an impressive 36.1% growth over
In line with this, 44,000 new chemist outlets were added during FY2026, with further plans to add 1,00,000 chemists by FY2027. On the cost front, the Company anticipated COGS inflation in FY2026 on account of the ongoing Middle East conflict impacting crude prices and global supply chains, a challenge it has partially mitigated through calibrated price increases. On the digital front, the Company has digitised 68% of
Narayanan Chief Sales Officer (till July 17, 2025) Mani Bhagavatheeswaran Chief Marketing Officer Dr. Ravichandran Associate Vice President – QC/ QA/R&D Soumomoy Pal Associate Vice President –Information Technology (till February 27, 2026) Jebasingh General Manager – Information Technology (w.e.f June 24, 2026) Distribution Expansion Cost Environment Digital Transformation Demand Outlook and Brand Strategy Capacity E
We believe our Company is well positioned to capitalize on these trends. With a clear strategy, trusted brands, expanding distribution, and strong execution capabilities, we are confident in our ability to meet evolving consumer needs while delivering sustainable, profitable growth and creating long-term value for our shareholders. In the OTC space, the successful expansion of brand Amrutanjan into modern format of R
Consumers are increasingly seeking convenient, accessible and trusted OTC solutions for common health conditions, supported by greater digital awareness and improved product accessibility across modern trade, pharmacies, e-commerce and quick commerce channels. While the industry continues to face periodic volatility arising from raw material prices, competitive intensity and evolving regulatory requirements, its long
Pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company at their meeting held on 8 May 2026, the Board has recommended the re- appointment of Mr. Swayambunathan Muralidharan as Non-Executive Independent Director, for a second term of five consecutive years commencing from June 29, 2026 up to June 28, 2031 which was subsequently approved by the shareholders
The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee,
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…